Tag: chronic lymphocytic leukemia (CLL)

1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. 2. Rates of high grade adverse events were similar between treatment groups. Evidence Rating Level: 1 (Excellent)   Study Rundown: CLL is a common hematologic malignancy often treated with a...
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. 2. Rates of high grade adverse events were similar between treatment groups. Evidence Rating Level: 1 (Excellent)   Study Rundown: CLL is a common hematologic malignancy often treated with...
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab. 2. Rates of adverse events in the two treatment groups were similar. Evidence Rating Level: 1 (Excellent)   Study Rundown: Many patients with CLL are elderly and have...
1. In untreated chronic lymphocytic leukemia (CLL) patients with coexisting conditions, patients treated with venetoclax–obinutuzumab experienced greater progression-free survival compared to patients treated with chlorambucil–obinutuzumab. 2. Rates of adverse events in the two treatment groups were similar. Evidence Rating Level: 1 (Excellent)   Study Rundown: Many patients with CLL are elderly and...